HealthCare Services

Dr. Michelle Kaku, MD is an Assistant Professor of Neurology at the Boston University School of Medicine. She is also the member of Amyloidosis Center, Boston…

Isabel Morgado, PhD

Dr. Isabel Morgado is working as a Scientist I at Nurix Therapeutics. She received her Ph.D. in Molecular Biology from the University of Algarve in Portugal,…

Rupali S. Avasare, MD

Dr. Avasare is Director of Glomerular Disease Program and Assistant Professor of Medicine, Division of Nephrology and Hypertension at Oregon Health & Science…

Giampaolo Merlini, MD

Dr. Giampaolo Merlini is the Director of the Center for Research and Treatment of Systemic Amyloidosis, and of the Biotechnology Research Laboratories, Scientific…

Giampaolo Merlini, MD

Dr. Giampaolo Merlini is the Director of the Center for Research and Treatment of Systemic Amyloidosis, and of the Biotechnology Research Laboratories, Scientific…

Talking With Your Doctor About hATTR Amyloidosis

Juris Janis Liepnieks, PhD

Alexion Pharmaceuticals Partners With Caelum Biosciences to Tackle Light Chain Amyloidosis

Alexion Pharmaceuticals (ALXN) has been one of the greatest growth stories in the ultra-rare disease space over the past decade, with their blockbuster C5 inhibitor…

Lawreen H. Connors, PhD

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.